Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma

NCT03604328 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-09-16

No results posted yet for this study

Summary

A single centre, open label, study to assess the safety, tolerability and biodegradation of PA5108 ocular implant in adults who have Open Angle Glaucoma (Primary or Secondary).

Conditions

  • Open-angle Glaucoma

Interventions

DRUG

PA5108

single ocular implant, administered on day 1

Sponsors & Collaborators

  • PolyActiva Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Nathan Kerr · The Royal Victorian Eye & Ear Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-24
Primary Completion
2020-06-15
Completion
2020-06-15

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03604328 on ClinicalTrials.gov